230 related articles for article (PubMed ID: 16713009)
1. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension.
Saiki A; Ohira M; Endo K; Koide N; Oyama T; Murano T; Miyashita Y; Shirai K
Diabetes Res Clin Pract; 2006 Dec; 74(3):242-8. PubMed ID: 16713009
[TBL] [Abstract][Full Text] [Related]
2. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
[TBL] [Abstract][Full Text] [Related]
3. Effect of combination therapy of benidipine hydrochloride and candesartan cilexetil on serum lipid metabolism and blood pressure in elderly hypertensive patients with type 2 diabetes mellitus.
Sasaki H; Kanai S; Oyama T; Miyashita Y; Yamamura S; Shirai K
J Atheroscler Thromb; 2006 Jun; 13(3):149-57. PubMed ID: 16835470
[TBL] [Abstract][Full Text] [Related]
4. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
Yang HY; Kao PF; Chen TH; Tomlinson B; Ko WC; Chan P
J Clin Pharmacol; 2007 Mar; 47(3):397-403. PubMed ID: 17322151
[TBL] [Abstract][Full Text] [Related]
5. Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome.
Saiki A; Oyama T; Endo K; Ebisuno M; Ohira M; Koide N; Murano T; Miyashita Y; Shirai K
Diabetes Res Clin Pract; 2007 Apr; 76(1):93-101. PubMed ID: 16956692
[TBL] [Abstract][Full Text] [Related]
6. The relationship of serum lipoprotein lipase mass with fasting serum apolipoprotein B-48 and remnant-like particle triglycerides in type 2 diabetic patients.
Kobayashi J; Nakajima K; Nohara A; Kawashiri M; Yagi K; Inazu A; Koizumi J; Yamagishi M; Mabuchi H
Horm Metab Res; 2007 Aug; 39(8):612-6. PubMed ID: 17712727
[TBL] [Abstract][Full Text] [Related]
7. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Fukuhara S; Iwasaka T
Thromb Res; 2006; 117(4):385-92. PubMed ID: 15896827
[TBL] [Abstract][Full Text] [Related]
8. Valsartan reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension.
Li QZ; Deng Q; Li JQ; Yi GH; Zhao SP
Clin Chim Acta; 2005 May; 355(1-2):131-6. PubMed ID: 15820487
[TBL] [Abstract][Full Text] [Related]
9. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
Nakamura T; Fujii S; Hoshino J; Saito Y; Mizuno H; Saito Y; Kurabayashi M
Hypertens Res; 2005 Dec; 28(12):937-43. PubMed ID: 16671331
[TBL] [Abstract][Full Text] [Related]
10. [Valsartan in patients with arterial hypertension and type 2 diabetes mellitus. The lapaval study].
Rodríguez Pérez JC; Novoa Novoa J; Caballero A; Anabitarte A; Plaza C; Palop L; Rodríguez Esparragón F
Nefrologia; 2005; 25(5):500-8. PubMed ID: 16392299
[TBL] [Abstract][Full Text] [Related]
11. Preheparin lipoprotein lipase mass is a practical marker of insulin resistance in ambulatory type 2 diabetic patients treated with oral hypoglycemic agents.
Hanyu O; Miida T; Kosuge K; Ito T; Soda S; Hirayama S; Wardaningsih E; Fueki Y; Obayashi K; Aizawa Y
Clin Chim Acta; 2007 Sep; 384(1-2):118-23. PubMed ID: 17651713
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
Zhu S; Liu Y; Wang L; Meng QH
Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
[TBL] [Abstract][Full Text] [Related]
13. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
Andrés A; Morales E; Morales JM; Bosch I; Campo C; Ruilope LM;
Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
[TBL] [Abstract][Full Text] [Related]
15. Coadministration of valsartan 160 and 320 mg and simvastatin 20 and 40 mg in patients with hypertension and hypercholesterolemia: a multicenter, 12-week, double-blind, double-dummy, parallel-group superiority study.
Rump LC; Baranova E; Okopien B; Weisskopf M; Kandra A; Ferber P
Clin Ther; 2008 Oct; 30(10):1782-93. PubMed ID: 19014834
[TBL] [Abstract][Full Text] [Related]
16. Effect of the angiotensin II receptor antagonist telmisartan on lipoprotein lipase mass in preheparin serum.
Hitsumoto T; Takahashi M; Iizuka T; Shirai K
J Atheroscler Thromb; 2008 Jun; 15(3):138-45. PubMed ID: 18603820
[TBL] [Abstract][Full Text] [Related]
17. [Clinical significance of preheparin serum lipoprotein lipase mass in normocholesterolemic patients with coronary artery disease].
Hitsumoto T; Yoshinaga K; Sakurai T; Aoyagi K; Matsumoto J; Iizuka T; Kaku M; Sugiyama Y; Kanai M; Uchi T; Noike H; Ohsawa H; Watanabe H; Shirai K
J Cardiol; 2002 Jul; 40(1):1-9. PubMed ID: 12166243
[TBL] [Abstract][Full Text] [Related]
18. Effects of valsartan and indapamide on plasma cytokines in essential hypertension.
Xie QY; Wang YJ; Sun ZL; Yang TL
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):629-34. PubMed ID: 17062919
[TBL] [Abstract][Full Text] [Related]
19. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan.
Saisho Y; Komiya N; Hirose H
Diabetes Res Clin Pract; 2006 Nov; 74(2):201-3. PubMed ID: 16737758
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of preheparin serum lipoprotein lipase mass by bezafibrate administration.
Totsuka M; Miyashita Y; Ito Y; Watanabe H; Murano T; Shirai K
Atherosclerosis; 2000 Nov; 153(1):175-9. PubMed ID: 11058713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
